Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07556107 · ClinicalTrials.gov registry record · Phase 4
The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)
A Phase 4 study, sponsored by Bassett Healthcare.
- Not yet
- Registry status
- Phase 4
- Development phase
- 852
- Enrollment target
NCT07556107: Clinical Trial Phase 4 study, sponsored by Bassett Healthcare.
NCT07556107 is a Phase 4 study that has not yet begun recruiting, run by Bassett Healthcare. The registered enrollment target is 852 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (64% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07556107, a Phase 4 study, has not yet begun recruiting, sponsored by Bassett Healthcare.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 852 participants
- Enrollment target
Study Summary
The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they can make better choices for their patients.
Primary Outcome
Difference between highest Scys (mg/L) post-treatment over 7 days minus Scys pre-treatment, expressed as ratio of pre-treatment level
Interventions
- DRUG meropenem
- DRUG Piperacillin + Tazobactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 852 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 4 |
What is known before NCT07556107 opens enrollment
NCT07556107 is an interventional study that assigns participants to a tested intervention. The registered 852 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (64% higher).
The record links to 0 conditions, and to 2 interventions - of which meropenem is the first listed.
NCT07556107 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07556107 about?
NCT07556107 is a clinical study titled "The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)". The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they...
What is the current status of trial NCT07556107?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 852 participants. The study started on 2026-06-01. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT07556107?
The interventions under investigation include: meropenem (DRUG), Piperacillin + Tazobactam (DRUG).
Who is sponsoring clinical trial NCT07556107?
This trial is sponsored by Bassett Healthcare, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07556107's enrollment target sits among peer trials
852 88th of 2000 higher than 1,913 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06237452 · 852 participants · Phase 3
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
- NCT06422143 · 851 participants · Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- NCT07005102 · 854 participants · Phase 2
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- NCT07290491 · 854 participants · Phase 3
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI